drugset / Trial / NCT05246670
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy
Phase 2
Active not recruiting
88 enrolled
Academic and Community Cancer Research United
National Cancer Institute (NCI) · collab
RandomizedParallel-groupDouble-blindSupportive care
Summary
This phase II trial tests whether PEA works to relieve the symptoms of chemotherapy-induced peripheral neuropathy in patients with cancer. Chemotherapy-induced peripheral neuropathy refers to a nerve problem that causes pain, numbness, tingling, or muscle weakness in different parts of the body, and is caused by chemotherapy. PEA may be useful against bothersome nerve symptoms.
Timeline
- Start
- 2022-05-16
- Primary completion
- 2024-02-12
- Completion
- 2026-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palmidrol | Small molecule | — | Oral |